TICKERNERD
Menu
TXGTXGHealthcare · Medical Devices

TXG Stock Forecast: 10X Genomics, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$76
−5.65% on the day

The 19 Wall Street analysts covering 10X Genomics, Inc. hold a median 12-month price target of $60 — -21.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 6 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$12.7B
Ticker Nerd rank
93 / 100
Median analyst target
$60
Analysts covering
19
Revenue$151.0M−12.6% y/y
Operating income−$23.0M
Net income−$17.9M
Free cash flow$15.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.8%
1M
+21.5%
YTD
+366.6%
1Y
+556.0%
From 52W high
−22.1%
From 52W low
+563.5%
$11
$98
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TXG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores 10X Genomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Accruals
95
Quality
94
Revisions
83
Value
71
Issuance
62
Growth
48
Volatility
43
Size
15

Momentum (97): The shares have been drifting up relative to others.

Volatility (43): The share price moves around a lot.

Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TXG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TXG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26TXGHigh $90Median $60Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
7 Buy12 Hold0 Sell
Low $40Median $60High $90

The green dot is the last close — the median target sits −21.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
29 Sept 2026Leerink PartnersMaintainsMarket Perform$40 → $90
28 Sept 2026Argus ResearchInitiatesBuy$110
28 Sept 2026Piper SandlerMaintainsNeutral$47 → $80
9 Sept 2026UBSMaintainsNeutral—
9 Sept 2026UBSMaintainsNeutral$20 → $68
1 Sept 2026RBC CapitalInitiatesSector Perform—
1 Sept 2026RBC CapitalInitiatesSector Perform$70
12 Aug 2026Stephens & Co.MaintainsOverweight$50 → $65
12 Aug 2026Stephens & Co.MaintainsOverweight—
10 Aug 2026Canaccord GenuityMaintainsBuy$50 → $60
10 Aug 2026Canaccord GenuityMaintainsBuy—
10 Aug 2026Piper SandlerMaintainsNeutral—
10 Aug 2026Piper SandlerMaintainsNeutral$42 → $47
7 Aug 2026CitigroupMaintainsNeutral—
7 Aug 2026CitigroupMaintainsNeutral$45 → $50
7 Aug 2026Morgan StanleyMaintainsEqual-Weight$37 → $40
7 Aug 2026Morgan StanleyMaintainsEqual-Weight—
17 July 2026Leerink PartnersMaintainsMarket Perform—
17 July 2026Leerink PartnersMaintainsMarket Perform$23 → $40
14 July 2026Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TXG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TXG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, 10X Genomics, Inc. returned +556.0% against +17.4% for the S&P 500, dividends included.

TXG vs S&P 500, last 12 monthsTotal return, rebased to 100
0200400600800Jan 26Apr 26Jul 26Oct 26TXGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TXG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

10X Genomics, Inc. (TXG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−279.8×

Cheaper than 99% of US stocks

Price / sales
20.6×

Cheaper than 9% of US stocks

Price / book
15.4×

Cheaper than 6% of US stocks

EV / EBITDA
−297.6×

Cheaper than 98% of US stocks

Growth & margins
Revenue growth (YoY)
−12.7%

Higher than 14% of US stocks

Earnings growth (YoY)
−12.6%

Higher than 25% of US stocks

Gross margin
74.5%

Higher than 87% of US stocks

Operating margin
−15.2%

Higher than 23% of US stocks

Net margin
−12.2%

Higher than 19% of US stocks

Returns & dividend
Return on equity
−9.4%

Higher than 36% of US stocks

Return on assets
−5.0%

Higher than 32% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

10X Genomics, Inc. (TXG) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • 10X Genomics, Inc. has a market value of $12.7B and an enterprise value of $12.3B.

  • Revenue in the twelve months to 30 June 2026: $616.9M. The latest quarter shrank 12.7% year on year.

  • Net income over the same four quarters: −$75.1M, a −12.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.59.

  • Free cash flow in the twelve months to 30 June 2026: $121.4M.

  • Shares outstanding: 130.3M.

  • Trailing P/E: −279.8×; forward P/E: 1274.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • 10X Genomics, Inc. employs 1,178 people — $524K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

TXG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TXG10X Genomics, Inc.$12.7B
93
GMEDGlobus Medical, Inc.$10.3B
96
BIOBio-Rad Laboratories, Inc.$9.9B
91
GKOSGlaukos Corp.$9.5B
92
PODDInsulet Corp.$9.3B
89
BRKRBruker Corp.$9.2B
87
PENPenumbra, Inc.$12.5B
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own 10X Genomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TXG news & analysis

10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

PRNewsWire · 7 Oct 2026positive

10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to apply single-cell and spatial technologies across solid tumors and blood cancers. Projects include bladder cancer biomarker discovery and residual disease detection in acute myeloid leukemia.

Why it matters — The collaboration highlights research applications of 10x Genomics’ technologies in cancer biomarker discovery and disease detection.

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises

Zacks Investment Research · 30 Sept 2026positive

10x Genomics has begun shipping its Atera systems after receiving orders for over 40 systems, reflecting strong early demand and broad research interest in its spatial biology platform.

Why it matters — TXG watchers would care because initial order demand for the Atera platform suggests growing adoption of the company's spatial biology technology.

10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions

PRNewsWire · 29 Sept 2026positive

10x Genomics announced Sentira, a new cloud analysis platform that extends its workflow from data generation to experimental conclusions, starting with Sentira Spatial Analysis. The platform leverages NVIDIA accelerated computing to reduce spatial data processing times from hours to minutes.

Why it matters — For TXG watchers, this product announcement signals an expansion of 10x's offering beyond data generation into computational analysis, potentially strengthening its position in the spatial biology market.

10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands

PRNewsWire · 29 Sept 2026positive

10x Genomics announced the first commercial shipments of Atera, a spatial biology platform, marking a major milestone following extraordinary early global demand and an expansive technology roadmap. The shipments mark the beginning of a new era in biological understanding.

Why it matters — TXG watchers would care because the commercial launch and global rollout of its Atera platform signal a significant step in expanding the company's spatial biology portfolio and commercial momentum.

3 Analysts, 3 Trades to Make Today

InvestorPlace · 22 Sept 2026neutral

The article "3 Analysts, 3 Trades to Make Today" from InvestorPlace presents trading recommendations from analysts, with one analyst (Louis) suggesting buying the AI dip. No specific mention or analysis of 10X Genomics is included in the text.

Why it matters — A TXG watcher would care because the article reflects current market sentiment around technology and AI-related trading, though the excerpt provides no direct commentary on 10X Genomics itself.

FAQ

Frequently asked questions about TXG stock

What is the TXG stock price forecast for 2026-2027?

The 19 Wall Street analysts covering 10X Genomics, Inc. have a median 12-month price target of $60, with estimates ranging from $40 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TXG stock a buy right now?

Of the 19 analysts covering 10X Genomics, Inc., 7 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 10X Genomics, Inc. 93 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TXG?

As at 6 Oct 2026, 10X Genomics, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will TXG stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies -21.2% from the last close, and Ticker Nerd's factor model ranks 10X Genomics, Inc. 93 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TXG stock forecast for 2030?

No analyst covering 10X Genomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TXG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $90 over the next 12 months.

How has TXG stock performed over the past year?

10X Genomics, Inc. returned +556.0% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does 10X Genomics, Inc. do?

10x Genomics Inc. Class A Common Stock represents ownership in 10x Genomics, a life science technology company focused on products that help researchers study biology at high resolution.

What is the latest news on TXG?

The most recent item we track (PRNewsWire, 7 Oct 2026): "10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers". 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to apply single-cell and spatial technologies across solid tumors and blood cancers. Projects include bladder cancer biomarker discovery and residual disease detection in acute myeloid leukemia.

Company

About 10X Genomics, Inc.

10x Genomics Inc. Class A Common Stock represents ownership in 10x Genomics, a life science technology company focused on products that help researchers study biology at high resolution. The company develops integrated instruments, consumables, and software used for single-cell and spatial biology workflows, supporting applications such as gene expression analysis, immune profiling, chromatin accessibility, spatial transcriptomics, and in situ exploration of tissue biology. Its main product families include the Chromium platform, the Chromium X series, Visium, and Xenium, which are used by academic researchers, pharmaceutical companies, biotechnology firms, and other scientific organizations. 10x Genomics serves global markets across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. The stock is commonly associated with the broader life sciences tools and services sector, where the company plays a specialized role in enabling advanced biological research and data generation.

CEO Dr. Serge Saxonov Ph.D. · 1,178 employees · United States · https://www.10xgenomics.com